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ABSTRACT
The present ﬁrst-in-human clinical trial evaluated the safety and feasibility of a newly developed
and cryopreserved Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product
from healthy donors for intramyocardial injection in ten patients with ischemic heart disease and
ischemic heart failure (IHF). Batches of CSCC_ASC were isolated from three healthy donors by lipo-
suction from abdominal adipose tissue. Adipose mesenchymal stromal cells were culture expanded
in bioreactors without the use of animal constituents, cryopreserved, and stored in vials in nitro-
gen dry-storage containers until use. Direct injection of CSCC_ASC into the myocardium did not
cause any complications or serious adverse events related to either treatment or cell administra-
tion in a 6-month follow-up period. Four out of ten heart failure patients developed donor-speciﬁc
de novo human leukocyte antigen (HLA) class I antibodies, and two out of ten patients had donor-
speciﬁc HLA antibodies already at baseline. There were no clinical symptoms or changes in inﬂam-
matory parameters in the follow-up period that indicated an ongoing immune response. There was
a tendency toward improvement in cardiac function after CSCC_ASC treatment at 6-month follow-
up: left ventricular end systolic volume decreased and left ventricular ejection fraction increased.
In addition, exercise capacity increased. These changes were independent of the presence or
absence of HLA antibodies. It is concluded that the newly developed cryopreserved product
CSCC_ASC from healthy donors was a safe and feasible treatment. We observed a tendency toward
efﬁcacy in patients with IHF. These ﬁndings have to be conﬁrmed in larger placebo controlled clini-
cal trials. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1963–1971
SIGNIFICANCE STATEMENT
This first-in-human study of an off-the-shelf cryopreserved Cardiology Stem Cell Centre adipose-
derived stromal cell product from healthy donors demonstrated safety, feasibility, and a tend-
ency toward clinical efficacy in ten patients with ischemic heart disease and heart failure. The
presence of a ready-to-use cryo-stored cell product will eliminate many of the logistic barriers
in disseminating cell therapy to many patient groups and will also reduce the cost of the
treatments.
INTRODUCTION
Coronary artery atherosclerosis causing ischemic
heart disease (IHD) is the most common cause of
death, with more than 17 million deaths world-
wide each year, and is a major cause of hospital
admissions in industrialized countries [1]. Estab-
lished therapies have reduced mortality of IHD
signiﬁcantly but have left an increasing number of
symptomatic patients with chronic IHD and/or
ischemic heart failure (IHF) without further treat-
ment options.
Stem cell therapy with mesenchymal stromal
cells, originating from different tissues, has
emerged as a new regenerative therapeutic tool
in this patient group as well as in several other
debilitating diseases for which no cure is currently
available. Clinical studies have been conducted
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with autologous bone marrow-derived mesenchymal stromal cells
(BMSCs) and adipose-derived stromal cells (ASCs) in patients with
IHD and IHF [2–4]. The treatments have been safe and the efﬁcacy
has been promising.
Our group has completed three clinical trials with fresh cul-
ture expanded autologous BMSCs and ASCs of approximately 150
patients with chronic IHF and IHD [5–9]. From these studies, we
have realized, that the use of autologous cells is highly complex
and hampers standardization and smooth logistics in this treat-
ment modality: autologous BMSCs and ASCs must be culture
expanded from each individual patient in order to reach an
adequate amount of cells for treatment. There seems to be a sig-
niﬁcant between-patient variation in cell yield and expansion
time. A previous study has demonstrated that kidney function,
chronic obstructive pulmonary disease, and use of steroids are
related to the number of mesenchymal stromal cells (MSCs)
reached after culture expansion [10]. In addition, intervention
with fresh cells faces great logistic challenges such as transporta-
tion and timing of treatment. To minimize donor variability and
the inﬂuence of patient comorbidities on product quality, we have
shifted focus from autologous to allogeneic ASC therapy by using
young and healthy volunteer donors of adipose tissue. The use of
allogeneic MSCs is perceived viable because these cells are
immune evasive. They have both regenerative and immunomodu-
latory properties—most intriguingly immunosuppressive ones
[11–13]. As such, it is rendered probable that these cells evade
being recognized by a recipient immune system, therefore allow-
ing allogeneic use. Allogeneic MSCs and ASCs have already been
used in clinical trials without any side effects [14–16].
With an eye on feasibility during manufacturing, standardiza-
tion, and product reproducibility, we have implemented produc-
tion in semi-automated closed bioreactor systems instead of
manual handling of ﬂasks and also the use of human platelet
lysate instead of fetal bovine serum as a growth supplement
[17–19]. Finally, we have abandoned fresh cell delivery and have
developed a cryopreserved off-the-shelf product to improve clini-
cal applicability.
The aim of the present phase I safety study was to test the
safety proﬁle and feasibility of our newly developed, cryopre-
served, and allogeneic ASC product from healthy donors in
patients with IHF.
MATERIALS AND METHODS
Study Design
A single-center ﬁrst-in-human phase I study to investigate the
safety and efﬁcacy of direct intramyocardial injections of the Car-
diology Stem Cell Centre adipose-derived stromal cell product
(CSCC_ASC) in ten patients with chronic IHF.
The study protocol complies with the Declaration of Helsinki
and was approved by the Danish National Committee on Health
Research Ethics (No. 1404435) and Danish Medicines Agency
(Eudra-CT: 2014-002980-13). The study is registered at clinical-
Trials.gov (NCT02387723). The local Good Clinical Practice Unit
monitored the study.
Study Population
The study included patients between 30 and 80 years of age with
chronic IHF, reduced left ventricular ejection fraction (LVEF;
45%), New York Heart Association (NYHA) class II–III, no further
revascularization options, and on maximal tolerable medical ther-
apy. The patients were all enrolled and treated at Rigshospitalet
University Hospital Copenhagen. Inclusion and exclusion criteria
are described in Supporting Information Appendix 1.
Study Procedures and Timeline
There was at least 1 week between treatments of each of the ﬁrst
three patients in order to observe and evaluate safety of the ther-
apy. Thereafter, the remaining seven patients were treated. All
patients stayed in-hospital at least 1 day after treatment. Patient
follow-up visits were done after 1, 2, 3, and 6 months, and
patients were evaluated clinically, with blood analyses for hemo-
globin, leukocytes, platelets, sodium, potassium, creatinine, high-
sensitivity CRP (hs-CRP), creatine kinase MB (CKMB), troponin,
and human leukocyte antigen (HLA) antibodies.
At baseline, and at 3- and 6-month follow-up, 6-minute walk-
ing tests (6MWT), Canadian Cardiovascular Society (CCS) and New
York Heart Association (NYHA) classiﬁcations, and Kansas City Car-
diomyopathy Questionnaires (KCCQ) were performed. Cardiac
computed tomography (CT) scans or echocardiography (ECHO)
were performed at baseline and 6 months after treatment.
Donors
Lipoaspirates were obtained from three healthy female donors
(28–33 years old). Donor eligibility was determined by a donor
interview, a questionnaire, and testing for infectious disease
markers HIV, hepatitis B and C, and syphilis by serum analyses
within 30 days prior to liposuction. In addition, a blood sample
was drawn on the day of donation for repeated serology and
nucleic acid testing of HIV, and hepatitis B and C. Donor testing
was performed by the Virus Laboratory, The Blood Bank, Depart-
ment of Clinical Immunology, Rigshospitalet, University of Copen-
hagen, as authorized by The Danish Patient Safety Authority. The
use of lipoaspirate has been approved by competent authorities
as mentioned above. All donors signed an informed consent.
Production of CSCC_ASC
Liposuction was performed from abdominal adipose tissue by an
experienced plastic surgeon, with local anesthesia, and in full com-
pliance with surgical procedures for sterile cosmetic surgery. Lipo-
suction was performed at the Department of Plastic Surgery,
Breast Surgery and Burns, Rigshospitalet and at Printzlau Private
Hospital, Virum, Denmark. Between 100 and 150 mL of abdominal
adipose tissue was obtained from each donor.
Preparation of lipoaspirates, isolation of stromal vascular frac-
tions (SVF), and expansion of cells in Quantum Cell Expansion Sys-
tems was performed at Cardiology Stem Cell Centre, as previously
described [17–19]. In short, SVF was isolated by enzymatic diges-
tion from each lipoaspirate, and expansion of cells was performed
in a two-passage expansion process in the semi-automated Quan-
tum Cell Expansion System. Cell culture medium was Minimum
Essential Medium, MEM Alpha (aMEM) without ribonucleosides
and deoxyribonucleosides, (Gibco, Gaithersburg, MD, https://
www.thermoﬁsher.com/us/en/home/brands/gibco.html; Life
Technologies, Durham, NC, https://www.thermoﬁsher.com/us/en/
home.html), 1% penicillin/streptomycin (100 U/mL and 100 mg/
mL, respectively; Gibco, Life Technologies) and 5% Stemulate
(human platelet lysate, Cook Regentec, Indianapolis, IN, http://
www.cookregentec.com/). For the purpose of cryo storage as a
ready-to-use product, the ﬁnal cell product constituting 110 mil-
lion ASCs in 5 mL cryopreservation media (CryoStor10, Biolife
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Solutions, Bothell, WA, http://www.biolifesolutions.com/) was
portioned into CellSeal vials (Cook Regentec).
Freezing was performed with a controlled rate freezer, Kryo
560–16 (Planer PLC, Sunbury-on-Thames, United Kingdom,
https://planer.com/). After freezing, vials were stored in a CBS-
v1500 Isothermal all dry-storage system (Custom Biogenic Sys-
tems, Bruce Township, MI, http://www.custombiogenics.com/)
below21808C.
Preparing for treatment, CellSeal vials were thawed in a 378C
water bath. Cell suspensions were aspirated with a needle into a
sterile syringe. The syringe was subsequently connected to the
MYOSTAR injection catheter (Biological Delivery System, Cordis,
Hialeah, FL, https://www.cordis.com/global-home.html; Johnson
& Johnson, New Brunswick, NJ, https://www.jnj.com/) for injec-
tion. Injection was performed within 1 hour of thawing.
Quality Control
CSCC_ASC was released for clinical use based on cell number, via-
bility, donor serology, sterility, and ASC characterization according
to the International Society for Cellular Therapy (ISCT) and the
International Federation for Adipose Therapeutics and Science
(IFATS) criteria (Supporting Information Appendix 2) [18, 19].
Total number of cells and percentage viability was determined
with a NucleoCounter NC-100 (Chemometec, Allerød, Denmark,
https://chemometec.com/) based on detection of ﬂuorescence
from the DNA binding dye, propidium iodide. Microbiological
quality control on ﬁnal cell product was performed with a fully
validated protocol using aerobic and anaerobic BacT/ALERT iFN
and iFA plus culture bottles (Biomerieux, Durham, NC, http://
www.biomerieux-usa.com/) and the BacT/ALERT Microbial Detec-
tion System (Biomerieux). Presence of mycoplasmas in cell culture
supernatants was detected by polymerase chain reaction (PCR)
for mycoplasma genus DNA at Statens Serum Institute, Copenha-
gen, Denmark. The content of endotoxins was quantitatively
determined by the limulus amebocyte lysate chromogenic end-
point method, by Statens Serum Institute. Immunophenotyping of
ASCs was performed by ﬂow cytometry according to ISCT and
IFATS standards [20, 21].
The following markers were used for release criteria (Sup-
porting Information Appendix 2): cluster of differentiation
(CD)45-ﬂuorescein isothiocyanate (FITC), HLA-DR-FITC, CD90-
FITC, CD73-phycoerythrin (PE) (all Beckman Coulter, Pasadena,
CA, https://www.beckmancoulter.com/), and CD105-PE (R&D Sci-
ences, Denmark). An extended panel of ISCT/IFATS markers was
used for research purpose. A compensated six-color protocol
including isotypic controls and Fluorescence Minus One tubes
was used (Navios ﬂow cytometer, Beckman Coulter). Viability
was determined with SYTOX blue (SYTOX, Invitrogen, Carlsbad,
CA, https://www.thermoﬁsher.com/us/en/home/brands/invitro-
gen.html; Life Technologies). Dead cells were excluded from the
ﬁnal analysis and data were analyzed using Navios software and
Kaluza (Beckman Coulter).
Genomic stability as determined by comparing ASCs at initial
and ﬁnal passage with comparative genomic hybridization (CGH)
was performed by Department of Clinical Genetics, Rigshospitalet,
Copenhagen University Hospital. CGH was performed using the
Agilent SurePrint G3 Human CGH Microarray kit 8_60K (design ID
021924) with 41 Kb overall median probe spacing (Agilent Tech-
nologies, Cary, NC, http://www.agilent.com/). Arrays were ana-
lyzed using an Agilent SureScan Microarray scanner and the
Agilent Feature Extraction software (v11.5), and results were pre-
sented by Agilent Genomic Workbench (v.7.0).
Table 1. Demographic data of the 10 patients with ischemic heart
failure
Parameters n5 10, n (%)
Age, years6 SD 62.56 6.6
Gender, male 7 (70)
BMI, kg/m26 SD 30.26 6.7
LVEF, %6 SD 28.86 4.1
Smoking
Current 2 (20)
Previous 4 (40)
Never 4 (40)
Diabetes mellitus 3 (30)
Hypertension 5 (50)
Hypercholesterolemia 9 (90)
Previous AMI 10 (100)
Previous CABG 4 (40)
Previous PCI 7 (70)
Systolic blood pressure, mmHg6 SD 1236 15
Diastolic blood pressure, mmHg6 SD 736 10
Pro-BNP, pmol/L6 SD 846 61
6MWT, meter6 SD 4356 87
Treatment with
Beta-blocker 9 (90)
ACE-inhibitor 9 (90)
Diuretic 6 (60)
Nitrate 4 (40)
Statin 9 (90)
Abbreviations: 6MWT, 6-minute walking test; ACE-inhibitors, angioten-
sin-converting-enzyme inhibitor; AMI, acute myocardial infarction;
BMI, body mass index; CABG, coronary artery by-pass grafting; LVEF,
left ventricular ejection fraction; n, number of patients; PCI, percutane-
ous voronary intervention; pro-BNP, pro-brain natriuretic peptide.
Table 2. Serious adverse events and adverse events within the 6-
month follow-up period in 10 patients after treatment with Cardiol-
ogy Stem Cell Centre adipose-derived stromal cell
Serious adverse events n5 3 Patient no.
Death 1 6
Hospitalizations
Unstable angina pectoris 1 3
Dyspnea 1 3
Adverse events n5 9 Patient no.
Pneumonia 1 3
Deterioration heart failure 3 1, 3, 5
Herpes Zoster 2 5, 8
Bleeding from rectum–colonoscopy normal 1 5
Febrile–virus 1 1
Insomnia problems 1 10
Deterioration of treated depression 1 3
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The residual amount of penicillin has been measured by liquid
chromatography-mass spectrometry in representative samples of
treatment vials during development. Due to a thorough washing
procedure, the amount of residual penicillin is found to be of no
risk with regard to causing allergic reactions; amounts are lower
than ﬁrst doses used for intravenous desensitization protocols
[22].
HLA Tissue Typing and of HLA Tissue Antibodies
Measurements
All donors had an intermediate resolution typing of HLAs (HLA)-A,
B, C, DRB1, DRB345, DQA1, DQB1, DPA1, DPB1 loci by real-time
PCR with subsequent melting point analyses using a Linkseq 384-
well complete typing kit (Linkage Biosciences, San Francisco, CA,
https://www.linkagebio.com/). The patients had a measurement
of anti-HLA antibodies in serum before as well as 1, 2, 3 and 6
months after the treatment. The LABScreen HLA class I and II sin-
gle antigen bead assay on a Luminex 100 (One Lambda, Inc.,
Thermo Fisher, Canoga Park, CA, http://www.onelambda.com/)
was used. Tests were performed in accordance with the manufac-
turer’s instructions and laboratory standard operating procedures
for clinical samples. Trimmed mean values were normalized for
background and expressed as mean ﬂuorescence intensity (MFI).
Cut-off for positivity was deﬁned as MFI 1.000. The laboratory
performance of the analyses was accredited by the European Fed-
eration of Immunogenetics.
NOGA-Guided Injection
A 3D electromechanical mapping of the left ventricle endocar-
dium was created with the NOGA system (Biologics Delivery
Table 3. Development of donor HLA-speciﬁc antibodies
Donor-speciﬁc HLA antibodies (MFI)
Donor HLA typing Patient Allele Baseline 1 month 2 months 3 months 6 months
1 A*01; B*08; C*07 1 (-) (-) (-) (-) (-)
DRB1*03; DQB1*02 2 (-) (-) (-) (-) (-)
3 (-) (-) (-) (-) (-)
4 B*08 (-) (-) (-) 2000 N/Aa
2 A*02; B*07,*57; C*06,*07; 5 B*57 (-) 4000 2000 1500 (-)
DRB1*07,*15; DQB1*03,*06 6 A*02 (-) 2000 3000 4000 2000
B*07 (-) (-) (-) (-) 2000
B*57 (-) 6000 7000 8000 3000
7 B*07 2500 4000 3500 3500 1500
DR15 6500 10500 11500 11000 7000
8 A*02 13000 15000 12000 16500 4000
B*07 8000 16000 13000 15000 6000
B*57 (-) 11000 16500 10100 7500
3 HLA-A*02,*B40,*44; C*02,*05; 9 A*02 (-) (-) (-) 1000 2500
DRB1*04,*13;DQB1*03,*06 10 (-) (-) (-) (-) (-)
Serum alloantibodies matching donor genotypes were evaluated at ﬁxed time points spanning 6 months. To illustrate titers semiquantitatively, MFI
is listed for detected allele.
aPatient passed away (unrelated cause). (-): MFI< 1,000.
Abbreviations: HLA, human leukocyte antigen; MFI, median ﬂuorescence intensity.
Table 4. Changes in cardiac function, exercise capacity, and symptoms from baseline to 6 months after direct intramyocardial injections of
Cardiology Stem Cell Centre adipose-derived stromal cell
95% conﬁdence
interval
Functional parameters n Baseline 6-month follow-up Difference SD Lower Upper p valuea
LVESV 9 205 mL 182 mL 223 mL 34 23 49 .073
LVEF 9 28.8% 31.7% 2.9% 4.1 0.2 6.1 .065
LVEDV 9 285 mL 279 mL 6 mL 26 214 26 .503
6MWT 8 460 m 495 m 35 m 14 24 47 <.0001
KCCQ QoL 9 67 65 1.9 17.6 212 15 .760
NYHA 10 2.8 2.2 0.6 0.8 0 1.2 .063
CSS 10 0.8 0.7 0.1 0.7 20.4 0.6 .655
a
p value between groups for differences.
Abbreviations: 6MWT, 6-minute walking test; CCS, Canadian Cardiovascular Society angina classiﬁcation; KCCQ, Kansas City Cardiomyopathy Ques-
tionnaire; LVEDV, left ventricle end-diastolic volume; LVEF, left ventricle ejection fraction; LVESV, left ventricle end-systolic volume; m, minutes;
NYHA, New York Heart Association classiﬁcation; QoL, quality of life.
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Systems, CA, Cordis Corporation, Johnson & Johnson Company,
US) using a NOGA Myostar catheter (Biological Delivery System).
Approximately 15 injections of 0.3 mL CSCC_ASC (total 100 mil-
lion) were injected via transendocardial stem cell injection into
viable myocardium in the border zone of infarcted tissue.
Endpoints
The primary endpoint was major immunologic reaction of alloge-
neic CSCC_ASC therapy with respect to incidence and severity of
serious adverse events and suspected unrelated serious adverse
events. To be open for all potential serious events, we had not, in
the protocol, speciﬁed events in details. However, we were look-
ing for immunologic reactions, death, hospitalization for worsen-
ing heart failure including inserting of a biventricular pacemaker,
and hospitalization due to ventricular tachycardia or ﬁbrillation,
cardiac perforation, and pericardial tamponade.
The secondary endpoints were improvements in left ventricle
end-systolic volume (LVESV), LVEF, and left ventricle end-diastolic
volume (LVEDV) at 6-month follow-up. Other secondary endpoints
were NYHA classiﬁcation, CCS angina classiﬁcation, KCCQ, 6MWT,
and development of donor antibodies at 6-month follow-up.
Cardiac CT Acquisition and Analysis
A 320-multidetector CT scanner (Aquilion One, Toshiba Medical
Systems Corporation, Otawara, Japan, http://www.toshibamedi-
calsystems.com/) was used to perform a cardiac CT scan before
and 6 months after therapy, as described previously [8, 23, 24].
The R-R interval and multisegmental image reconstruction was
performed with the scanner software. Images were reconstructed
with 0.5 mm slice thickness and increments of 0.25 mm in 2%
interval in the prospective window.
Participants underwent a standard transthoracic echocardio-
graphic examination using Philips cardiovascular ultrasound sys-
tem with a X5–1 probe (Philips, Cardiovascular, US) for standard
ECHO. Images were stored for ofﬂine analysis.
All image data was analyzed with the CVI42 post-processing
tool (Circle Cardiovascular Imaging, Calgary, Alberta, Canada,
https://www.circlecvi.com/). Endocardial and epicardial borders
Figure 1. Cardiac function, exercise capacity and symptoms before and 6 months after treatment with Cardiology Stem Cell Centre adipose-
derived stromal cell. Mean6 SD. Abbreviations: KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEDV, left ventricle end-diastolic volume;
LVEF, left ventricle ejection fraction; LVESV, left ventricle end-systolic volume; NYHA, New York Heart Association classiﬁcation.
Kastrup, Haack-Sørensen, Juhl et al. 1967
www.StemCellsTM.com Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
were traced manually in end-diastole and end-systole, and the
mitral plane set to deﬁne the basal border of the left ventricle.
Statistics
Analyzes were performed using the statistical software SPSS ver-
sion 23.0 (SPSS Inc., Chicago, Illinois, http://www.ibm.com/ana-
lytics/us/en/technology/spss/). Continuous variables are
presented as mean6 standard deviation and categorical variables
are presented as numbers and percentages.Within group compar-
ison were analyzed using paired t test for continuous data and
Wilcoxon signed ranks test for categorical data. Between groups
comparisons were analyzed with Student’s t test. A two-tailed
probability value less than .05 was considered to indicate statisti-
cal signiﬁcance.
RESULTS
Patients
A total of ten patients (seven men and three women; mean age:
62.56 6.6 years) with stable IHF were included in the study.
Demographic data are presented in Table 1.
Cell Characteristic
Immunophenotype. CSCC_ASC phenotype was in accordance
with ISCT and the Joint statement of the IFATS [20, 21]. Release
criteria are shown in Supporting Information Appendix 2.
Genomic Stability. Array CGH analysis of cells from the donors
demonstrated that ASCs expanded in vitro in Quantum Cell Expan-
sion devices in the presence of humane platelet lysate did not
show imbalanced chromosomal rearrangements.
Microbial Tests. Microbial tests for aerobic and anaerobic bac-
teria, fungus of ﬁnal cell preparations, and mycoplasmas from cul-
ture supernatants were all negative. The endotoxin concentration
in all ﬁnal cell preparations was less than 10 IU/mL.
Safety
Each patient was treated with cells from one of three donors, and
no matching between the donor and the patient tissue types was
performed. There were no procedure-related complications to the
direct intramyocardial injection of CSCC_ASC.
One patient died 6 months after treatment during a hospitali-
zation for a knee bacterial bursitis with cardiac complications. This
event was not related to the stem cell treatment. One patient had
two hospitalizations due to unstable angina pectoris and dysp-
noea, respectively. Coronary angiography was without any new
lesions, and diuretic treatment was intensiﬁed (Table 2).
During the 6-month follow-up period, four out of ten patients
developed donor-speciﬁc de novo HLA class I antibodies, and two
other patients had donor-speciﬁc antibodies at baseline (Table 3).
None of the patients had any clinical symptoms or changes in bio-
chemical parameters (leukocytes, high-sensitive CRP) or inﬂamma-
tory signs indicating an immunization.
An expected increase and decrease in troponins and CKMB,
respectively, after the intramyocardial injection of cells was seen
(data not shown). There was no increase in hemoglobin, leuko-
cytes, platelets, sodium, potassium, creatinine, hs-CRP, CKMB, and
troponin in the follow-up period (data not shown).
Efficacy
The cardiac function tended to improve after CSCC_ASC treatment
at 6-month follow-up: LVESV decreased from 205 mL to 182 mL
with a difference of 23 mL (95% conﬁdence interval [CI]: 23 to
49; p5 .073), and LVEF increased from 28.8% to 31.7%, with a dif-
ference of 2.9% (95% CI: 0.2 to 6.1; p5 .065). In addition, 6MWT
increased from 460 minutes to 495 minutes, with a difference of
35 minutes (95% CI: 24 to 47; p< .0001), and NYHA class from 2.8
to 2.2, with a difference of 0.6 (95% CI: 0 to 1.2; p5 .06) 6 months
after therapy (Table 4; Fig. 1).
There were no differences in KKCQ scores and CCS class in the
follow-up period (Table 4). Plasma pro-brain natriuretic peptide
was unchanged from baseline (846 61 pmol/L) to 6-month fol-
low-up (87.86 23.9 pmol/L; p5 .38).
The development of tissue type-speciﬁc donor antibodies
seemed to have no negative effect on cardiac function, exercise
capacity, and symptoms 6 months after treatment with CSCC_ASC
(Table 5; Fig. 2).
DISCUSSION
The present study is the ﬁrst-in-human study of a newly devel-
oped cryopreserved off-the-shelf adipose-derived stromal cell
product (CSCC_ASC), developed from healthy donors without the
use of xenogeneic animal constituents while using a closed bio-
reactor system for culture expansion of cells. A total of 110 million
ASCs were injected directly into the myocardium with no compli-
cations or serious adverse events related to either treatment or
cell administration.
No pretreatment tissue type matchings between the donors
and the patients were carried out. Although two patients had
donor-speciﬁc HLA antibodies at baseline and four patients
developed donor-speciﬁc de novo HLA class I antibodies after
treatment, this seemed to have no inﬂuence on the efﬁcacy of
the cell product in patients with IHD and heart failure. De novo
antibodies were only directed against HLA class I antigens, as
expected, because CSCC_ASC does not present HLA class II
antigens.
Table 5. Inﬂuence of development of donor speciﬁc antibodies on
changes in cardiac function, exercise capacity and symptoms from
baseline to 6 months after direct intramyocardial injections of Car-
diology Stem Cell Centre adipose-derived stromal cell
Difference
Parameter
No antibodies
(n5 6)
Antibodies
(n5 3) p valuea
LVESV (mL) 216.56 33.6 236.26 36.0 .44
LVEF (%) 3.66 4.0 1.66 4.7 .52
LVEDV (mL) 26.86 32.4 24.56 4.1 .91
6MWT (m) 35.96 15.5 33.56 9.2 .85
KCQoL 21.76 19.9 22.16 17.2 .97
NYHA 20.76 0.8 20.56 1.0 .78
All values are mean differences1 standard deviation.
a
p value between groups for differences.
Abbreviations: 6MWT, 6-minute walking test; CCS, Canadian Cardiovas-
cular Society angina classiﬁcation; KCCQ, Kansas City Cardiomyopathy
Questionnaire; LVEDV, left ventricle end-diastolic volume; LVEF, left
ventricle ejection fraction; LVESV, left ventricle end-systolic volume; m,
minutes; NYHA, New York Heart Association classiﬁcation.
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It is a limitation that HLA antibodies were measured continu-
ously for each patient during the study period, as this does not
allow direct comparisons of MFI values between samples for each
patient due to day-to day variation in the laboratory.
Although not powered to demonstrate any efﬁcacy, the
CSCC_ASC treatment demonstrated a tendency toward an
improvement in left ventricle pump function and a reduction in
dilatation of the left ventricle. Although these ﬁndings have to be
conﬁrmed in a larger clinical trial, they display the same tendency
that we have previously demonstrated in a larger double-blind
placebo-controlled study in patients with heart failure treated
with autologous BMSCs. [8] In addition, the present study found a
signiﬁcant improvement in 6MWT.
As demonstrated for autologous cell therapy, the ﬁndings
strongly support the hypothesis that allogeneic mesenchymal
stromal cells are safe and efﬁcacious. Moreover, there seems to
be no need for immunosuppressive treatment concomitant with
the allogeneic cell therapy. The present study extends the previous
demonstration of safety using the autologous adipose-derived
SVF treatment of patients with chronic ischemic cardiomyopathy
(Precise Trial), non-ischemic dilated cardiomyopathy (POSEIDON-
DCM Trial), and patients with acute myocardial infarction (Apollo
Trial) [25–27].
The overall aim was to establish a logistically and clinically
applicable off-the shelf stem cell treatment strategy for patients.
We changed from autologous to allogeneic cells, and we imple-
mented a more standardized and reproducible stem cell produc-
tion platform using semi-automated closed bioreactor systems
instead of ﬂasks and human platelet lysate instead of fetal bovine
serum, as well as cryo storage of a ready-to-use product [7–19].
Figure 2. The inﬂuence of development of donor-speciﬁc tissue type antibodies on cardiac function, exercise capacity, and symptoms before
and 6 months after treatment with Cardiology Stem Cell Centre adipose-derived stromal cell. Mean6 SD. The * in LVESV indicates that the
SD is outside the lower border of the ﬁgure. Abbreviations: 6MWT, 6-minute walking test; KCCQ, Kansas City Cardiomyopathy Questionnaire;
LVEDV, left ventricle end-diastolic volume; LVEF, left ventricle ejection fraction; LVESV, left ventricle end-systolic volume; NYHA, New York
Heart Association classiﬁcation; QoL, quality of life.
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We have in the present study demonstrated that it is feasible
to generate a reproducible, standardized, and clinically applicable
cell product from healthy donors that is safe and has a very prom-
ising efﬁcacy proﬁle.
One obvious consequence of using a cryopreserved cell prod-
uct for clinical treatment is the use of cryopreservation formulas
holding dimethyl sulfoxide (DMSO). Clinical side effects have been
related to the amount of DMSO administered; however, with
given intramyocardial administration, a total amount of only 0.5 g
DMSO, distributed in 15 injections, does not give rise to any side
effects. This is in accordance with previous publications in which
intramyocardial and intravenous injection of cells in excipients
holding DMSO were proven safe in clinical studies for heart dis-
eases [27–29].
It is a common strategy for the sake of standardization and
optimization of efﬁcacy to produce allogeneic mesenchymal stro-
mal cell products from one donor only. However, this limits dis-
semination when a new donor eventually has to be included due
to increased scale of treatments and the inevitable senescence of
the original stromal cell line.We have used cell product from three
donors, which induces a higher degree of variability in cell prod-
ucts and potentially also in clinical efﬁcacy. However, it also
extends the safety proﬁle and the efﬁcacy to a more general use
of donors, which can be a beneﬁt in the long run, after implemen-
tation of the therapy as a more general treatment option.
CONCLUSION
The present study was a phase I study with no control group.
Therefore, some of the efﬁcacy ﬁndings are potentially due to a
placebo effect. Also, the study was not powered to evaluate efﬁ-
cacy, and statistical results should be viewed with this in mind. To
further evaluate the safety and efﬁcacy of this newly developed
allogeneic ASC product, larger double-blind placebo-controlled
clinical trials are needed in patients with IHF.
In conclusion, the present ﬁrst-in-human study of the newly
developed allogeneic ASC product CSCC_ASC from healthy donors
stored frozen as an off-the-shelf product demonstrated safety and
feasibility when injected directly into the myocardium in patients
with IHF.
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